Renal replacement therapy associated with lithium nephrotoxicity in Australia
Date
2014
Authors
Roxanas, M.
Grace, B.
George, C.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Medical Journal of Australia, 2014; 200(4):226-228
Statement of Responsibility
Milton Roxanas, Blair S Grace, Charles R P George
Conference Name
Abstract
OBJECTIVE: To analyse the annual incidence of end-stage renal disease (ESRD) associated with lithium-induced nephropathy (LiN) in Australia. DESIGN, SETTING AND PARTICIPANTS: Retrospective cohort study of patients commencing renal replacement therapy (RRT) in Australia. We compared patients with LiN with all other RRT patients between 1 January 1991 and 31 December 2011, using Australia and New Zealand Dialysis and Transplant Registry data. MAIN OUTCOME MEASURES: Numbers and characteristics of incident RRT patients, primary kidney disease (LiN or other, based on clinical diagnosis). RESULTS: LiN contributed to 187 people in Australia commencing RRT between 1 January 1991 and 31 December 2011. The incidence rate increased from 0.14 cases/million population/year (95% CI, 0.06-0.22) in 1992-1996 to 0.78 (95% CI, 0.67-0.90) in 2007-2011. This increase is unlikely to be attributed solely to demographic changes in Australia. LiN patients were more likely than non-LiN patients to be women, to be white, to smoke, and to have a higher body mass index, but were less likely to have undergone renal biopsy. CONCLUSIONS: Rates of ESRD attributed to LiN are increasing rapidly. Currently accepted lithium dosages and duration of treatment might induce ESRD in a large cohort of patients. We encourage clinicians to exercise discretion when prescribing lithium, check renal function regularly, stop lithium if there is a deterioration in two consecutive readings, and consider substitution with other drugs.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Copyright status unknown